RecruitingNCT07608003

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

Application of MRI-Based Artificial Intelligence Models for Preoperative Molecular Subtyping and Prognostic Assessment of Midline Gliomas: A Multicenter Prospective Clinical Study


Sponsor

Xiangya Hospital of Central South University

Enrollment

500 participants

Start Date

May 10, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.


Eligibility

Inclusion Criteria3

  • Patients with diffuse gliomas were pathologically and molecularly diagnosed.
  • The clinical case data of all patients were complete.
  • Patients underwent preoperative MRI examination.

Exclusion Criteria2

  • The tumor is not located in the intracranial midline.
  • Cases in which MRI were incomplete or with significant noise and artifacts.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Xiangya Hospital of Central South University

Changsha, Hunan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07608003


Related Trials